genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as nash - nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). genfit is committed to contribute to bringing new medicines to market for patients who lack suitable solutions, and strives to implement mutually beneficial approaches that combine novel drugs and biomarkers. its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including genfit’s lead proprietary compound, gft505, that is completing a phase 2b study in nash.
Company profile
Ticker
GNFT, GNFTF
Exchange
Website
CEO
Pascal Prigent
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GNFT stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
5 Apr 24
20-F
2023 FY
Annual report (foreign)
5 Apr 24
6-K
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
4 Apr 24
6-K
Current report (foreign)
29 Feb 24
6-K
GENFIT Announces 2024 Financial Calendar
17 Jan 24
6-K
Current report (foreign)
11 Jan 24
6-K
Current report (foreign)
8 Dec 23
6-K
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
7 Dec 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
8.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 7 |
Closed positions | 0 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 6.20 bn |
Total shares | 4.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Partners | 2.64 mm | $10.18 mm |
Tang Capital Management | 1.23 mm | $4.37 bn |
Optiver Holding B.V. | 296.61 k | $1.05 bn |
Old Mission Capital | 84.03 k | $297.48 mm |
Envestnet Asset Management | 41.35 k | $146.36 mm |
MS Morgan Stanley | 39.66 k | $140.41 mm |
O'shaughnessy Asset Management | 32.42 k | $114.78 mm |
Two Sigma Investments | 14.37 k | $50.85 mm |
UBS UBS Group AG - Registered Shares | 4.33 k | $15.33 mm |
BNP Paribas Arbitrage | 1.80 k | $6.37 mm |